Here is the corrected translation with Yifeng changed to Efung.
Monthly Health Reader | April 2026
On April 28, the Political Bureau of the CPC Central Committee held a meeting to analyze the economic situation and deploy work priorities. The meeting emphasized the need to implement, with precision and effectiveness, a more proactive fiscal policy and a moderately accommodative monetary policy, to boost domestic demand and drive industrial upgrading, and to strive for a good start to the 15th Five-Year Plan period. This has sent a clear signal to the market: capital will be directed toward technological innovation fields aligned with national strategies, particularly "hard tech" domains that can propel industrial transformation.
As one of China's earliest professional investment institutions focusing on the biomedicine and high-end medical device sectors, Efung Capital has long adhered to the strategy of "investing early, in small-sized enterprises, and in hard tech," moving in sync with the national agenda. This month, several of Efung Capital's portfolio companies have reported significant financing progress and operational breakthroughs.
01 Portfolio Companies: Financing and Listing Progress
Nuradi
· Nuradi Completes Series E Financing with Major "National Team" Investment in the Radiopharmaceutical Sector
In April, Nuradi announced the completion of its Series E financing round, raising over RMB 1 billion. This is the largest disclosed financing event in the domestic radiopharmaceutical sector so far this year.
TNM A
· Sci-Tech Innovation Board IPO Application Approved by SSE Listing Committee
On April 3, TNM A's Sci-Tech Innovation Board IPO application successfully passed the review meeting of the Shanghai Stock Exchange's Listing Committee.
SuperDimension Exploration
· SuperDimension Exploration N++ Completes Seed Financing
Recently, SuperDimension Exploration announced the completion of a tens of millions of RMB seed round financing, co-invested by Efung Capital and Shenzhen Shiqin Investment.
HaploX
· HaploX Goes Public via Backdoor Listing
Recently, Hong Kong-listed company Lingrui Holdings issued a joint announcement, disclosing that HaploX, a leading genetic testing company, through its wholly-owned offeror, successfully acquired 560,140,000 shares of Lingrui Holdings for a total consideration of approximately HKD 133 million, marking HaploX's official entry into the Hong Kong capital market via a backdoor listing.
Yingte Micro
· Completes Tens of Millions RMB in Pre-A+ Financing
Recently, Yingte Micro completed tens of millions of RMB in Pre-A+ financing, with this round led by Efung Capital.
Dingchi Bio
· Dingchi Bio Completes New Round of Tens of Millions RMB Financing
Recently, Dingchi Bio officially announced the completion of a new round of tens of millions of RMB financing, with this round exclusively invested by Efung Capital.
02 Portfolio Companies: Clinical and Commercial Updates
HighLight Pharma
· Brain-penetrant NLRP3 Inhibitor HL-400 Completes US Phase I Clinical Trial
On April 2, HighLight Pharma announced that its brain-penetrant NLRP3 inhibitor HL-400 has completed Phase I clinical trials in the United States.
· Positive Topline Data from Phase III Clinical Trial of Ginnoxitinib (TLL-018) for Rheumatoid Arthritis
Recently, HighLight Pharma announced positive topline results from the Phase III clinical trial (TARA study) of its orally administered small molecule JAK1/TYK2 inhibitor Ginnoxitinib for the treatment of active rheumatoid arthritis.
Huiguan Bio
· Debut of New Product at Exhibition
On April 10, Huiguan Bio showcased multiple representative products in its light-sheet microscopy imaging series, officially launching the PilotView High-content Intelligent Light-sheet Microscopy Imaging System.
IASO Bio
· International Partnership with Brazil's Butantan Institute to Develop Innovative Therapies for Hematological Malignancies
On April 10, IASO Bio announced the signing of a technology cooperation licensing agreement with Butantan Institute, a leading public institution in Brazil, to develop CAR-T cell therapies for hematological malignancies locally in Brazil.
· CCTV 2 Visits IASO Bio's Production Base
Recently, CCTV 2's financial channel visited IASO Bio's production base located in the Nanjing Biomedical Valley.
Weigao Medical
· First Multi-center Live Broadcast in Interventional Robotics Industry Redefines the Future of Interventional Surgery
Recently, at CIT2026 (the 24th Annual Conference on Interventional Cardiology of the Chinese Medical Association), Weigao Medical partnered with four major cardiovascular centers across China to tackle four highly challenging lesion types in the PCI field.
Hua Mei Hao Lian
· Contributed to White Paper; Case Study Formally Included
From April 23 to 24, the "AI Agent Empowering Industry Decision-Making: Trends and Practices White Paper (2026)" was officially released at the 2026 Annual Academic Conference of the Intelligence and Intelligent Cognition Committee. Hua Mei Hao Lian was invited to contribute to the white paper, with the company's AI R&D Director Wu Lei serving as an expert in the editorial team. The project "Hua Doctor AI Agent Empowering an Insurance Institution" was listed as a typical practice case in the white paper.
Genuine Bio
· Azvudine and Doxitinib Combination Therapy Presented at AACR 2026
Recently, as the American Association for Cancer Research (AACR 2026) annual meeting took place in the United States, Genuine Bio presented preclinical research results of the combination therapy of Azvudine and Doxitinib in a poster session.
Yingli Pharma
· First Patient Enrolled in Phase II Clinical Trial of Novel HIPK2 Allosteric Inhibitor RLA-23174
Recently, Yingli Pharma announced the successful enrollment of the first patient in the Phase II clinical trial of its novel small molecule HIPK2 allosteric inhibitor RLA-23174 tablets, co-developed with Rila Therapeutics.
Dingchi Bio
· Advancing Needle-free Veterinary Epidemic Prevention
Recently, the Porcine Epidemic Diarrhea Subunit Vaccine (293S32 Strain), jointly submitted by Beijing Dingchi Bio, its subsidiary Zhejiang Dingchi Bio-products, Jiangsu Academy of Agricultural Sciences, Taizhou Guotai Technology Innovation Center for Veterinary Biologics, and Jiangsu Leju Medical, successfully obtained a clinical trial approval from China's Ministry of Agriculture and Rural Affairs.
Senmai Medical
· Expanding to Indonesia for Win-win Cooperation
Recently, Senmai Medical's core team traveled to Indonesia for business inspections and cooperation negotiations, reaching in-depth cooperation agreements with Indonesia's national health insurance agency, local healthcare systems, and authoritative social organizations regarding electronic injection pens and digital medication management solutions.
Canton Biotech
· RNA-LNP Lyophilization Production Line Commences Operations, Accelerating Next-generation RNA Drug Delivery
In April, Canton Biotech's RNA-LNP lyophilization production line officially commenced operations, further enhancing the company's full-chain service capabilities in the RNA drug formulation sector.
Westlake Omics
· Showcases "AI + Spatiotemporal" Core Matrix at CCTB Conference
From April 24 to 26, the China Tumor Biomarkers Conference (CCTB) took place in Chengdu, where Westlake Omics presented its "AI + Spatiotemporal" core matrix.
Century Kangtai
· Universal Hydrophobic Preloaded Intraocular Lens ASOB55LPS Successfully Added to National Centralized Procurement
On April 16, the National Joint Procurement Office for High-Value Medical Consumables officially released the announcement of additional products for the centralized volume-based procurement of intraocular lenses and sports medicine consumables. Century Kangtai's independently developed next-generation universal hydrophobic intraocular lens (Model: ASOB55LPS) was successfully added to the national centralized procurement catalog.
· Successful Implantations of Vanshian Lens at Multiple Hospitals
Recently, hospitals including Quanzhou Aier Eye Hospital and Tianjin Medical University General Hospital successfully completed implantations of the Vanshian® Ultra-EDoF lens.
Hua High Thyme
· Four Clinical Study Results of Utidelone Presented Simultaneously
On April 21, the latest clinical data from four studies on Hua High Thyme's core products, Utidelone Injection (UTD1) and Utidelone Capsules (UTD2), were presented as poster displays at ASCO 2026.
03 Portfolio Companies: New Drug and Device Approvals
Shengsi Bio
· NMPA Accepts Marketing Application for FRSW117 Ultra-long-acting Recombinant Factor VIII
On April 29, Shengsi Bio announced that the marketing application for its PEGylated recombinant human coagulation factor VIII-Fc fusion protein (Project Code: FRSW117) has been submitted to and formally accepted by China's National Medical Products Administration (NMPA).
CircRNA Bio
· HM2003 Receives FDA Fast Track Designation
On April 13, CircRNA Bio announced that its core circular RNA innovative drug, HM2003 injection, has successfully received Fast Track designation from the U.S. Food and Drug Administration (FDA).
Tianqin Bio
· Supported Binhe Bio's mRNA New Drug to Obtain FDA IND Clearance
Recently, Binhe Bio's self-developed LNP-delivered IL-2 analog mRNA candidate drug BR003 received Investigational New Drug (IND) clearance from the U.S. FDA. Tianqin Bio's Wuhan branch undertook the non-clinical toxicology and pharmacokinetic studies for BR003.
04 Portfolio Company Honors
Included in CDE's "Starlight Plan"
· Ascentage Pharma: MDM2-p53 Inhibitor APG-115
Won Top 5 Best Medical Services Investment Cases in 2025 China Healthcare Service Industry (CV Awards)
· Hua Mei Hao Lian
Won Top 10 Best Medical Device Investment Cases in 2025 China Healthcare Service Industry (CV Awards)
· Core Medical, Nuoerkang
Listed in 2026 China Future Unicorn Enterprises Top 100 & Hangzhou Quasi-Unicorn Enterprises List (10th Annual Everything Grows Conference)
· Lingyi Bio
Recognized as a 2026 Outstanding Employer by 51job
· TNM A
Designated as "Above-scale Industrial Enterprise" by Wuhan Municipal Bureau of Economy and Information Technology
· Huiguan Bio
Re-listed as a "Hangzhou Quasi-Unicorn Enterprise" at the Everything Grows Conference
Named as a 2025 Hangzhou "New Young Eagle" Enterprise
· Westlake Omics
Won the High-end Medical Equipment "2026 Breakthrough Innovation Award" at HighMed Expo
· Zifu Medical: Capsule Endoscopy System
05 Efung Capital Honors
CV Awards
Efung Capital:
2025 Best China RMB-denominated VC Institution TOP 50
2025 Top 20 Medical Device Investment Institutions in China's Healthcare Service Industry
2025 Best VC Institution in China TOP 100
Efung Capital CEO Zhu Pai:
FOF Research Center
Efung Capital CEO Zhu Pai: